LT2002031A - Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai - Google Patents

Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai

Info

Publication number
LT2002031A
LT2002031A LT2002031A LT2002031A LT2002031A LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A LT 2002031 A LT2002031 A LT 2002031A
Authority
LT
Lithuania
Prior art keywords
prevention
treatment
mesoprogestins
disorders
progesterone receptor
Prior art date
Application number
LT2002031A
Other languages
English (en)
Other versions
LT5034B (lt
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of LT2002031A publication Critical patent/LT2002031A/lt
Publication of LT5034B publication Critical patent/LT5034B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Šiame išradime yra aprašomi mezoprogestinai - nauja progesterono receptoriaus moduliatorių (PRM) klasė, skirta panaudoti gerybinių nuo hormonų priklausomų ginekologinių sutrikimų gydymui ir prevencijai: a) ginekologinių sutrikimų, tokių kaip endometriozė, gimdos fibromos, pooperaciniai pilvaplėvės suaugimai, kraujavimo funkcijos sutrikimai (metroragija, menoragija) ir dismenorėja, gydymui; b) ginekologinių sutrikimų, tokių kaip pooperaciniai pilvaplėvės suaugimai, gimdos kraujavimo funkcijos sutrikimai (metroragija, menoragija) ir dismenorėja, prevencijai, ir c) moteriškos lyties gyvūnų, ypatingai moterų, kurioms yra reikalingas vieno ar daugiau tokių sutrikimų gydymas, gydymui arba prevencijai, naudojant efektyvų mezoprogestino kiekį. Mezoprogestinais yra vadinami junginiai, kurie turi ir agonistinį, ir antagonistinį poveikį į progesterono receptorių (PR) in vivo. Jie stabilizuoja PR funkciją tarpiniame lygmenyje tarp agonistinio ir antagonistinio. Atitinkamų funkcinių būsenų negalima pasiekti naudojant progestinus arba antiprogestinus. Mezoprogestinų dienos dozė yra 0,5-100 mg, geriau 5,0-50 mg, o geriausia 10-25 mg. Pagal šį išradimą tinkamiausiais mezoprogestinais yra J867, J912, J956 ir J1042.ą
LT2002031A 1999-08-31 2002-03-21 Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai LT5034B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38614199A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
LT2002031A true LT2002031A (lt) 2003-02-25
LT5034B LT5034B (lt) 2003-07-25

Family

ID=23524338

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002031A LT5034B (lt) 1999-08-31 2002-03-21 Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai

Country Status (34)

Country Link
EP (1) EP1229906B1 (lt)
JP (1) JP2003535029A (lt)
KR (3) KR20080066095A (lt)
AR (1) AR025457A1 (lt)
AT (1) ATE375160T1 (lt)
AU (1) AU781840B2 (lt)
BG (1) BG65817B1 (lt)
BR (1) BR0014161A (lt)
CA (1) CA2382580C (lt)
CO (1) CO5200772A1 (lt)
CZ (1) CZ2002704A3 (lt)
DE (1) DE60036723T2 (lt)
DK (1) DK1229906T3 (lt)
EA (1) EA007854B1 (lt)
EE (1) EE05172B1 (lt)
ES (1) ES2295050T3 (lt)
HR (1) HRP20020267A2 (lt)
HU (1) HUP0202429A3 (lt)
IL (1) IL148416A0 (lt)
LT (1) LT5034B (lt)
LV (1) LV12941B (lt)
ME (1) MEP13808A (lt)
MX (1) MXPA02002191A (lt)
NO (1) NO20020999L (lt)
NZ (1) NZ517471A (lt)
PE (1) PE20010578A1 (lt)
PL (1) PL198790B1 (lt)
PT (1) PT1229906E (lt)
RO (1) RO122179B1 (lt)
RS (1) RS50283B (lt)
SI (1) SI20852B (lt)
SK (1) SK287192B6 (lt)
UA (1) UA78184C2 (lt)
WO (1) WO2001015679A2 (lt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014935A1 (de) * 2002-08-02 2004-02-19 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
US20040097591A1 (en) * 2002-11-18 2004-05-20 Kristof Chwalisz Use of selective progesterone receptor modulators for the treatment of androgen deficiency
RU2301691C1 (ru) * 2005-12-20 2007-06-27 Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Российской академии медицинских наук Способ восстановительного лечения женщин репродуктивного возраста с тазовыми перитонеальными спайками с фиксированной или субфиксированной ретродевиацией матки
DE102007011105A1 (de) 2007-03-02 2008-09-04 Bayer Schering Pharma Aktiengesellschaft Mineralcorticoid-Rezeptor-Antagonisten zur Behandlung von Endometriose
RU2339392C1 (ru) * 2007-05-21 2008-11-27 Федеральное Государственное учреждение Научный центр акушерства, гинекологии и перинатологии Росмедтехнологий Способ остановки маточных кровотечений в пубертатном периоде
AU2010260885B2 (en) * 2009-06-17 2015-03-12 Keio University Prophylactic and/or therapeutic agent for dysmenorrhea
US8399432B2 (en) * 2009-10-27 2013-03-19 Lipogen Ltd. Compositions and methods of treatment for alleviating premenstrual syndrome symptoms
US20220339176A1 (en) * 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation
US12426782B2 (en) 2020-11-06 2025-09-30 The Board Of Trustees Of The Leland Stanford Junior University Systems and temporal alignment methods for evaluation of gestational age and time to delivery

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3633244A1 (de) 1986-09-26 1988-03-31 Schering Ag Antigestagene zur hemmung der uterinen prostaglandinsynthese
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5681817A (en) * 1994-02-04 1997-10-28 The Medical College Of Hampton Roads Treatment of ovarian estrogen dependent conditions
US5576310A (en) * 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
WO1996019458A2 (en) * 1994-12-22 1996-06-27 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5696130A (en) * 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Tricyclic steroid receptor modulator compounds and methods
SK282570B6 (sk) 1995-02-02 2002-10-08 Schering Aktiengesellschaft Antagonisty progesterónu na výrobu liekov na ošetrenie dysfunkčného maternicového krvácania
DE19604231A1 (de) * 1996-01-29 1997-07-31 Schering Ag Pharmazeutisches Kombinationspräparat und seine Verwendung zur Behandlung von gynäkologischen Störungen
DE69702450T2 (de) * 1996-05-01 2001-03-08 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer 21-substituierte progesteron derivate als antigestagene
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
BR9916999A (pt) * 1999-01-14 2001-10-30 Bayer Ag Heterociclos de 2-arilimino substituìdos ecomposições contendo-os, para uso como agentesde ligação do receptor de progesterona
WO2000066590A2 (en) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Tetracyclic progesterone receptor modulator compounds and methods

Also Published As

Publication number Publication date
HUP0202429A2 (en) 2002-10-28
JP2003535029A (ja) 2003-11-25
YU14002A (sh) 2006-01-16
BG65817B1 (bg) 2010-01-29
AR025457A1 (es) 2002-11-27
SK287192B6 (sk) 2010-02-08
SI20852A (sl) 2002-10-31
ES2295050T3 (es) 2008-04-16
EE200200104A (et) 2003-04-15
KR100864547B1 (ko) 2008-10-20
AU781840B2 (en) 2005-06-16
MXPA02002191A (es) 2002-09-30
NZ517471A (en) 2004-02-27
EA200200282A1 (ru) 2002-10-31
PE20010578A1 (es) 2001-06-04
UA78184C2 (en) 2007-03-15
LV12941B (en) 2003-06-20
MEP13808A (en) 2010-06-10
NO20020999D0 (no) 2002-02-28
ATE375160T1 (de) 2007-10-15
KR20080066095A (ko) 2008-07-15
SI20852B (sl) 2009-06-30
SK2992002A3 (en) 2002-07-02
KR100755109B1 (ko) 2007-09-04
PL353930A1 (en) 2003-12-15
WO2001015679A3 (en) 2001-11-22
LT5034B (lt) 2003-07-25
CA2382580A1 (en) 2001-03-08
HUP0202429A3 (en) 2004-04-28
DE60036723T2 (de) 2008-07-17
EA007854B1 (ru) 2007-02-27
CO5200772A1 (es) 2002-09-27
DE60036723D1 (de) 2007-11-22
DK1229906T3 (da) 2008-02-11
NO20020999L (no) 2002-03-14
CA2382580C (en) 2009-05-19
BR0014161A (pt) 2002-05-21
WO2001015679A2 (en) 2001-03-08
EP1229906B1 (en) 2007-10-10
IL148416A0 (en) 2002-09-12
BG106442A (bg) 2002-09-30
CZ2002704A3 (cs) 2003-02-12
HRP20020267A2 (en) 2004-04-30
RS50283B (sr) 2009-09-08
KR20020027616A (ko) 2002-04-13
PL198790B1 (pl) 2008-07-31
EE05172B1 (et) 2009-06-15
EP1229906A2 (en) 2002-08-14
RO122179B1 (ro) 2009-02-27
AU6946600A (en) 2001-03-26
KR20070058023A (ko) 2007-06-07
PT1229906E (pt) 2008-01-18

Similar Documents

Publication Publication Date Title
DK0792152T3 (da) Fremgangsmåder til svangerskabsforebyggelse
AU2561195A (en) Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
WO2004000801A3 (en) Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions
WO2004000225A3 (en) Use of thio-oxindole derivatives in treatment of hormone-related conditions
HK1045816A1 (zh) 角质细胞生长因子-2制剂
YU14002A (sh) Mezoprogestini (progesteron receptor modulatori) za lečenje i prevenciju benignih hormonskih ginekoloških poremećaja
WO2007016385A3 (en) Use of substituted 5-amino-1h-pyrrole-2-carbonitrile derivatives as progesterone receptor modulators
WO2001064236A3 (en) METHODS FOR TREATING FSH RELATED CONDITIONS WITH GnRH ANTAGONISTS
WO2000042031A3 (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2003022205A3 (en) Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
NZ515353A (en) Cyclothiocarbamate derivatives as progesterone receptor modulators
BG102682A (bg) Система за освобождаване на контрацептиви с бактерицидно и/или антивирусно действие
WO2002056903A3 (en) Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
WO2001026603A3 (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives
CL2003001544A1 (es) Compuestos derivados de 5-cicloalquenil-5h-cromeno[3,4-f]quinolina de formula i, moduladores selectivos del receptor de progesterona; composicion farmaceutica; y su uso en el tratamiento de sangrado uterino disfuncional, dismenorrea, endometriosis, l
WO2003022224A3 (en) Cox-2 function and wound healing
CA2467964A1 (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
WO2001011361A3 (en) Kit and method to assess the malignancy of neoplasias
EA200200285A1 (ru) Мезопрогестины (модуляторы рецептора прогестерона) в качестве компонента композиций для заместительной гормональной терапии (згт)
PT1159965E (pt) Utilizacao de um antagonista do receptor da progesterona para a prevencao ou inibicao da fertilizacao
Tsuga Full automatic vegetable transplanter
WO2002020526A3 (en) Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents
UA32302A (uk) Спосіб усунення післяопераційних деформацій м'яких тканин
HUP0200244A3 (en) Use of sex hormones for producing nasal pharmaceutical compositions useful in the treatment of undesirable uterine bleeding

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: SCHERING AKTIENGESELLSCHAFT, DE

Effective date: 20050104

MM9A Lapsed patents

Effective date: 20100831